Impact of COVID-19 in pediatric oncology care in Latin America during the first year of the pandemic.
COVID-19
Latin America
healthcare delivery
low- and middle-income countries
pediatric cancer
survey
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
23
03
2022
received:
23
01
2022
accepted:
04
04
2022
pubmed:
21
5
2022
medline:
30
8
2022
entrez:
20
5
2022
Statut:
ppublish
Résumé
The ongoing coronavirus 2019 disease (COVID-19) pandemic strained medical systems worldwide. We report on the impact on pediatric oncology care in Latin American (LATAM) during its first year. Four cross-sectional surveys were electronically distributed among pediatric onco-hematologists in April/June/October 2020, and April/2021 through the Latin American Society of Pediatric Oncology (SLAOP) email list and St Jude Global regional partners. Four hundred fifty-three pediatric onco-hematologists from 20 countries responded to the first survey, with subsequent surveys response rates above 85%. More than 95% of participants reported that treatment continued without interruption for new and active ongoing patients, though with disruptions in treatment availability. During the first three surveys, respondents reported suspensions of outpatient procedures (54.2%), a decrease in oncologic surgeries (43.6%), radiotherapy (28.4%), stem cell transplants (SCT) (69.3%), and surveillance consultations (81.2%). Logistic regression analysis showed that at the beginning of the first wave, participants from countries with healthcare expenditure below 7% were more likely to report a decrease in outpatient procedures (odds ratio [OR]: 1.84, 95% CI: 1.19-2.8), surgeries (OR: 3, 95% CI: 1.9-4.6) and radiotherapy (OR: 6, 95% CI: 3.5-10.4). Suspension of surveillance consultations was higher in countries with COVID-19 case fatality rates above 2% (OR: 3, 95% CI: 1.4-6.2) and SCT suspensions in countries with COVID-19 incidence rate above 100 cases per 100,000 (OR: 3.48, 95% CI: 1.6-7.45). Paradoxically, at the beginning of the second wave with COVID-19 cases rising exponentially, most participants reported improvements in cancer services availability. Our data show the medium-term collateral effects of the pandemic on pediatric oncology care in LATAM, which might help delineate oncology care delivery amid current and future challenges posed by the pandemic.
Sections du résumé
BACKGROUND
The ongoing coronavirus 2019 disease (COVID-19) pandemic strained medical systems worldwide. We report on the impact on pediatric oncology care in Latin American (LATAM) during its first year.
METHOD
Four cross-sectional surveys were electronically distributed among pediatric onco-hematologists in April/June/October 2020, and April/2021 through the Latin American Society of Pediatric Oncology (SLAOP) email list and St Jude Global regional partners.
RESULTS
Four hundred fifty-three pediatric onco-hematologists from 20 countries responded to the first survey, with subsequent surveys response rates above 85%. More than 95% of participants reported that treatment continued without interruption for new and active ongoing patients, though with disruptions in treatment availability. During the first three surveys, respondents reported suspensions of outpatient procedures (54.2%), a decrease in oncologic surgeries (43.6%), radiotherapy (28.4%), stem cell transplants (SCT) (69.3%), and surveillance consultations (81.2%). Logistic regression analysis showed that at the beginning of the first wave, participants from countries with healthcare expenditure below 7% were more likely to report a decrease in outpatient procedures (odds ratio [OR]: 1.84, 95% CI: 1.19-2.8), surgeries (OR: 3, 95% CI: 1.9-4.6) and radiotherapy (OR: 6, 95% CI: 3.5-10.4). Suspension of surveillance consultations was higher in countries with COVID-19 case fatality rates above 2% (OR: 3, 95% CI: 1.4-6.2) and SCT suspensions in countries with COVID-19 incidence rate above 100 cases per 100,000 (OR: 3.48, 95% CI: 1.6-7.45). Paradoxically, at the beginning of the second wave with COVID-19 cases rising exponentially, most participants reported improvements in cancer services availability.
CONCLUSION
Our data show the medium-term collateral effects of the pandemic on pediatric oncology care in LATAM, which might help delineate oncology care delivery amid current and future challenges posed by the pandemic.
Identifiants
pubmed: 35593012
doi: 10.1002/pbc.29748
pmc: PMC9347956
doi:
Substances chimiques
Suspensions
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29748Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Future Oncol. 2020 Jun;16(18):1225-1227
pubmed: 32356460
Neuro Oncol. 2020 Dec 18;22(12):1884-1886
pubmed: 32623465
Cancer. 2022 Feb 1;128(3):579-586
pubmed: 34618361
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
Ecancermedicalscience. 2020 Sep 24;14:1110
pubmed: 33144878
Cancer Invest. 2022 May;40(5):401-405
pubmed: 33866889
Pediatr Blood Cancer. 2022 Oct;69(10):e29748
pubmed: 35593012
Ecancermedicalscience. 2021 Jan 14;15:1172
pubmed: 33680086
JMIR Mhealth Uhealth. 2021 Jul 8;9(7):e29619
pubmed: 34255706
Int J Clin Oncol. 2021 Aug;26(8):1569-1574
pubmed: 34145514
Eur J Epidemiol. 2020 Aug;35(8):775-779
pubmed: 32785815
Lancet Oncol. 2020 Jun;21(6):753-755
pubmed: 32437662
J Clin Oncol. 2015 Sep 20;33(27):3065-73
pubmed: 26304881
Lancet Child Adolesc Health. 2021 May;5(5):332-340
pubmed: 33675698
Curr Opin Pediatr. 2013 Feb;25(1):3-15
pubmed: 23295716
Eur J Cancer. 2020 Jun;132:11-16
pubmed: 32305831
Health Serv Insights. 2020 Dec 28;13:1178632920984161
pubmed: 33447044
Pediatr Blood Cancer. 2020 Dec;67(12):e28519
pubmed: 32588962
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Pediatr Blood Cancer. 2020 Sep;67(9):e28346
pubmed: 32374054
Cancer. 2020 Sep 15;126(18):4235-4245
pubmed: 32648950
Br J Haematol. 2020 Jul;190(1):e5-e8
pubmed: 32369605
Lancet Oncol. 2020 Jun;21(6):750-751
pubmed: 32359403
Lancet Oncol. 2021 Oct;22(10):1416-1426
pubmed: 34454651
Med J Aust. 2022 Apr 4;216(6):312-319
pubmed: 35201615
Acta Biomed. 2020 Sep 07;91(3):e2020022
pubmed: 32921719
Lancet Oncol. 2021 Oct;22(10):1343-1345
pubmed: 34560005